RxDoctor Payments Data

David Kraklau, MD

Urology · Saint Joseph, MINPI 1033546122

Payments from drug & device makers

$2,989in general payments, 2019–2025

Across 109 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$476
  • Johnson & Johnson$206
  • Sumitomo Pharma America, Inc.$155
  • Myovant Sciences Inc.$127
  • Boston Scientific$120
  • plus $829 from 23 others

What the payments were for

  • Travel & lodging$82628%
  • Food & beverage$2,08470%
  • Education$793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,989 in reported general payments places this provider in the 50th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$84,298
Medicare patients
292
Services billed
1,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron31$21,370
MyrbetriqMirabegron17$12,576
Tamsulosin Hcl343$5,757
Finasteride183$2,540
Potassium Citrate ErPotassium Citrate19$2,077
Trospium Chloride19$1,503
Estradiol19$1,063
Alfuzosin Hcl ErAlfuzosin Hcl78$1,000
Dutasteride23$941
Oxybutynin Chloride ErOxybutynin Chloride34$851
Cephalexin73$402
Oxybutynin Chloride14$319
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$160
Fluconazole12$73
Amoxicillin18$46

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$155$21,37031 claims
Astellas Pharma US IncMyrbetriq$476$12,57617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 400 urology providers in Michigan.

Other urology in Saint Joseph

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →